Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
P-glycoprotein (P-gp) is a major factor in the multidrug resistance phenotype in cancer cells. P-gp is a protein that regulates the ATP-dependent efflux of a wide range of anticancer medicines and confers resistance. Due to its wide specificity, several attempts have been made to block the action of...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/6/897 |
| _version_ | 1797485182191665152 |
|---|---|
| author | Chenmala Karthika Raman Sureshkumar Mehrukh Zehravi Rokeya Akter Faraat Ali Sarker Ramproshad Banani Mondal Priti Tagde Zubair Ahmed Farhat S. Khan Md. Habibur Rahman Simona Cavalu |
| author_facet | Chenmala Karthika Raman Sureshkumar Mehrukh Zehravi Rokeya Akter Faraat Ali Sarker Ramproshad Banani Mondal Priti Tagde Zubair Ahmed Farhat S. Khan Md. Habibur Rahman Simona Cavalu |
| author_sort | Chenmala Karthika |
| collection | DOAJ |
| description | P-glycoprotein (P-gp) is a major factor in the multidrug resistance phenotype in cancer cells. P-gp is a protein that regulates the ATP-dependent efflux of a wide range of anticancer medicines and confers resistance. Due to its wide specificity, several attempts have been made to block the action of P-gp to restore the efficacy of anticancer drugs. The major goal has been to create molecules that either compete with anticancer medicines for transport or function as a direct P-gp inhibitor. Despite significant in vitro success, there are presently no drugs available in the clinic that can “block” P-gp–mediated resistance. Toxicity, unfavourable pharmacological interactions, and a variety of pharmacokinetic difficulties might all be the reason for the failure. On the other hand, P-gp has a significant effect in the body. It protects the vital organs from the entry of foreign bodies and other toxic chemicals. Hence, the inhibitors of P-gp should not hinder its action in the normal cells. To develop an effective inhibitor of P-gp, thorough background knowledge is needed in this field. The main aim of this review article was to set forth the merits and demerits of the action of P-gp on cancer cells as well as on normal cells. The influence of P-gp on cancer drug delivery and the contribution of P-gp to activating drug resistance were also mentioned. |
| first_indexed | 2024-03-09T23:16:02Z |
| format | Article |
| id | doaj.art-d453db2ab16944188fcdcbf84124d303 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T23:16:02Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-d453db2ab16944188fcdcbf84124d3032023-11-23T17:37:22ZengMDPI AGLife2075-17292022-06-0112689710.3390/life12060897Multidrug Resistance of Cancer Cells and the Vital Role of P-GlycoproteinChenmala Karthika0Raman Sureshkumar1Mehrukh Zehravi2Rokeya Akter3Faraat Ali4Sarker Ramproshad5Banani Mondal6Priti Tagde7Zubair Ahmed8Farhat S. Khan9Md. Habibur Rahman10Simona Cavalu11Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, Tamil Nadu, IndiaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, Tamil Nadu, IndiaDepartment of Clinical Pharmacy Girls Section, Prince Sattam Bin Abdul Aziz University Alkharj, Alkharj 11942, Saudi ArabiaDepartment of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju 26426, Gangwon-do, KoreaDepartment of Licensing and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority (BoMRA), Gaborone 999106, BotswanaDepartment of Pharmacy, Ranada Prasad Shaha University, Narayanganj 1400, BangladeshDepartment of Pharmacy, Ranada Prasad Shaha University, Narayanganj 1400, BangladeshAmity Institute of Pharmacy, Amity University, Noida 201303, Uttar Pradesh, IndiaUnit of Bee Research and Honey Production, Faculty of Science, King Khalid University, Abha 61413, Saudi ArabiaBiology Department, Faculty of Sciences and Arts, King Khalid University, Dhahran Al Janoub, Abha 61413, Saudi ArabiaDepartment of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju 26426, Gangwon-do, KoreaFaculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, RomaniaP-glycoprotein (P-gp) is a major factor in the multidrug resistance phenotype in cancer cells. P-gp is a protein that regulates the ATP-dependent efflux of a wide range of anticancer medicines and confers resistance. Due to its wide specificity, several attempts have been made to block the action of P-gp to restore the efficacy of anticancer drugs. The major goal has been to create molecules that either compete with anticancer medicines for transport or function as a direct P-gp inhibitor. Despite significant in vitro success, there are presently no drugs available in the clinic that can “block” P-gp–mediated resistance. Toxicity, unfavourable pharmacological interactions, and a variety of pharmacokinetic difficulties might all be the reason for the failure. On the other hand, P-gp has a significant effect in the body. It protects the vital organs from the entry of foreign bodies and other toxic chemicals. Hence, the inhibitors of P-gp should not hinder its action in the normal cells. To develop an effective inhibitor of P-gp, thorough background knowledge is needed in this field. The main aim of this review article was to set forth the merits and demerits of the action of P-gp on cancer cells as well as on normal cells. The influence of P-gp on cancer drug delivery and the contribution of P-gp to activating drug resistance were also mentioned.https://www.mdpi.com/2075-1729/12/6/897multidrug resistanceP-gpcancerinhibitorsclinical trials |
| spellingShingle | Chenmala Karthika Raman Sureshkumar Mehrukh Zehravi Rokeya Akter Faraat Ali Sarker Ramproshad Banani Mondal Priti Tagde Zubair Ahmed Farhat S. Khan Md. Habibur Rahman Simona Cavalu Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein Life multidrug resistance P-gp cancer inhibitors clinical trials |
| title | Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein |
| title_full | Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein |
| title_fullStr | Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein |
| title_full_unstemmed | Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein |
| title_short | Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein |
| title_sort | multidrug resistance of cancer cells and the vital role of p glycoprotein |
| topic | multidrug resistance P-gp cancer inhibitors clinical trials |
| url | https://www.mdpi.com/2075-1729/12/6/897 |
| work_keys_str_mv | AT chenmalakarthika multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT ramansureshkumar multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT mehrukhzehravi multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT rokeyaakter multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT faraatali multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT sarkerramproshad multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT bananimondal multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT prititagde multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT zubairahmed multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT farhatskhan multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT mdhabiburrahman multidrugresistanceofcancercellsandthevitalroleofpglycoprotein AT simonacavalu multidrugresistanceofcancercellsandthevitalroleofpglycoprotein |